Literature DB >> 22520483

[Renal abnormalities in ankylosing spondylitis].

Barbouch Samia1, Faiçal Hazgui, Khaoula Ben Abdelghani, Fethi Ben Hamida, Rym Goucha, Hafedh Hedri, Chokri Ben Taarit, Hedi Ben Maiz, Adel Kheder.   

Abstract

We will study the epidemiologic, clinical, biological, therapeutic, prognostic characteristics and predictive factors of development of nephropathy in ankylosing spondylitis patients. We retrospectively reviewed the medical record of 32 cases with renal involvement among 212 cases of ankylosing spondylitis followed in our service during the period spread out between 1978 and 2006. The renal involvement occurred in all patients a mean of 12 years after the clinical onset of the rheumatic disease. Thirty-two patients presented one or more signs of renal involvement: microscopic hematuria in 22 patients, proteinuria in 23 patients, nephrotic syndrome in 11 patients and decreased renal function in 24 patients (75%). Secondary renal amyloidosis (13 patients), which corresponds to a prevalence of 6,1% and tubulointerstitial nephropathy (7 patients) were the most common cause of renal involvement in ankylosing spondylitis followed by IgA nephropathy (4 patients). Seventeen patients evolved to the end stage renal disease after an average time of 29.8 ± 46 months. The average follow-up of the patients was 4,4 years. By comparing the 32 patients presenting a SPA and renal disease to 88 with SPA and without nephropathy, we detected the predictive factors of occurred of nephropathy: tobacco, intense inflammatory syndrome, sacroileite stage 3 or 4 and presence of column bamboo. The finding of 75% of the patients presented a renal failure at the time of the diagnosis of renal involvement suggests that evidence of renal abnormality involvement should be actively sought in this disease.
Copyright © 2011 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22520483     DOI: 10.1016/j.nephro.2011.10.005

Source DB:  PubMed          Journal:  Nephrol Ther        ISSN: 1769-7255            Impact factor:   0.722


  5 in total

1.  A case report on nephrotic syndrome associated with ankylosing spondylitis effectively treated with infliximab.

Authors:  Xin Feng; Yao Li; Wei Gao
Journal:  Int J Clin Exp Med       Date:  2014-09-15

2.  MEFV M694V mutation has a role in susceptibility to ankylosing spondylitis: A meta-analysis.

Authors:  Linqing Zhong; Hongmei Song; Wei Wang; Ji Li; Mingsheng Ma
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

3.  Membranous nephropathy in a patient with ankylosing spondylitis: A case report.

Authors:  Ruiying Chen; Fang Li; Qionghong Xie; Jun Xue; Lingyun Lai; Shaojun Liu; Liyin Zhang; Chuanming Hao
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

4.  Relative risk of end-stage renal disease requiring dialysis in treated ankylosing spondylitis patients compared with individuals without ankylosing spondylitis: A nationwide, population-based, matched-cohort study.

Authors:  Hsin-Hua Chen; Ching-Heng Lin; Kuo-Lung Lai; Tsu-Yi Hsieh; Yi-Ming Chen; Chih-Wei Tseng; Donald F Gotcher; Yu-Mei Chang; Chuang-Chun Chiou; Shih-Chia Liu; Shao-Jen Weng
Journal:  PLoS One       Date:  2020-04-20       Impact factor: 3.240

5.  Spondyloarthritis Patients Suffer Increased Risk of Renal Complications Compared With General Population: A Retrospective Observational Study.

Authors:  Min Xiao; Qing Lv; Yanli Zhang; Liudan Tu; Mingcan Yang; Zhiming Lin; Zetao Liao; Yutong Jiang; Xuqi Zheng; Xiaomin Li; Qiujing Wei; Shuangyan Cao; Jieruo Gu
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.